Nucleic Acid Constructs for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, especially systemic therapies, face challenges such as high toxicity and non-specific activity, limiting their effectiveness and acceptance. There is a need for methods that can specifically target cancer cells while minimizing harm to healthy tissues.
Innovation Solution
The use of nucleic acid constructs comprising a cancer-specific promoter, such as the PEG-3 promoter, and nucleic acid sequences encoding one or more tumor antigens, formulated into nanoparticles with a cationic polymer, to achieve targeted expression of therapeutic agents within the tumor microenvironment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic cancer treatments are administered, then anti-cancer activity is achieved, but toxicity in healthy tissues increases
Solution Approach 1:
The patent applies local quality by using cancer-specific promoters (such as PEG-3 promoter) that are active only in cancer cells, ensuring that therapeutic agents are expressed locally within the tumor microenvironment rather than systemically. This creates different functional properties in different tissues: high therapeutic activity in cancer cells and no activity in healthy tissues, thereby resolving the contradiction between anti-cancer effectiveness and healthy tissue toxicity
Solution Approach 2:
The patent uses cancer-specific promoters as intermediary elements that mediate between the therapeutic agent and the target cancer cells. These promoters act as selective switches that allow the therapeutic agent to be activated only in the presence of cancer cells, preventing inappropriate activation in healthy tissues and thus reducing toxicity while maintaining anti-cancer efficacy
2Reliability
If cancer-cell specific promoters are used to direct expression, then therapeutic specificity is improved, but expression levels may be reduced
Solution Approach 1:
The patent segments the therapeutic construct into distinct functional components: the cancer-specific promoter (PEG-3) that provides specificity, the therapeutic agent gene (such as IL-12) that provides therapeutic activity, and optional enhancer elements. This segmentation allows each component to be optimized independently - the promoter for specificity and the therapeutic gene for expression level - resolving the contradiction between specificity and expression quantity
Data Source
AI summary
The present disclosure provides nucleic acid constructs for the treatment of cancer, comprising a cancer-specific promoter and one or more therapeutic genes.